WO2015141978A1 - Composition pour maintenir l'efficacité d'une charge - Google Patents

Composition pour maintenir l'efficacité d'une charge Download PDF

Info

Publication number
WO2015141978A1
WO2015141978A1 PCT/KR2015/002294 KR2015002294W WO2015141978A1 WO 2015141978 A1 WO2015141978 A1 WO 2015141978A1 KR 2015002294 W KR2015002294 W KR 2015002294W WO 2015141978 A1 WO2015141978 A1 WO 2015141978A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
collagen
filler
hyaluronic acid
collagen hydrolyzate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2015/002294
Other languages
English (en)
Korean (ko)
Inventor
신현정
최진규
김병규
서대방
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amorepacific Corp
Original Assignee
Amorepacific Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020150030409A external-priority patent/KR20150110332A/ko
Application filed by Amorepacific Corp filed Critical Amorepacific Corp
Priority to US15/127,399 priority Critical patent/US10279076B2/en
Priority to CN201580018372.XA priority patent/CN106170309A/zh
Priority to SG11201607473PA priority patent/SG11201607473PA/en
Publication of WO2015141978A1 publication Critical patent/WO2015141978A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/26—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction

Definitions

  • the present invention relates to parenteral compositions that maintain the efficacy of the filler for a long time.
  • Hyaluronic acid which is a substance mainly used in such procedures, is known to be metabolized and excreted from a few days after being inserted or implanted into the human body regardless of the concentration of the substance or the type of composition containing the substance.
  • Non-Patent Document 1 Steed, D.L. et al., Clin. Plast. Surg. 25, 397, 1998
  • the composition for maintaining the hyaluronic acid filler efficacy, the composition for promoting hyaluronic acid synthesis and the parenteral for inhibiting hyaluronidase activity comprising a collagen hydrolysate as an active ingredient
  • the present invention provides a filler surgical kit comprising a hyaluronic acid filler composition and collagen hydrolyzate as an active ingredient.
  • composition according to the present invention is useful for promoting the synthesis of hyaluronic acid and inhibiting the activity of hyaluronidase, so that the hyaluronic acid filler efficacy can be maintained for a longer time. Accordingly, the effect can be maintained even if the filler is performed a few times, there is an advantage that the skin irritation is also reduced.
  • parenteral administration has the advantage that the method of administration is simple and can penetrate directly into the skin, thereby enabling an immediate effect.
  • Figure 1 is a graph showing that the amount of hyaluronic acid synthesis increased by the treatment of the collagen peptide.
  • the present invention relates to a parenteral composition for maintaining hyaluronic acid filler efficacy, comprising, as an active ingredient, a collagen hydrolyzate (hydrolyzed collagen) in one aspect.
  • a collagen hydrolyzate hydrolyzed collagen
  • Collagen is one of the light proteins and contains a small amount of sugar. It is the major constituent of connective tissue matrix and accounts for about 30% by weight of total protein in mammals. It is present in the dermis, cartilage, etc. in the fibrous form of the animal and becomes collagen fibers.
  • the basic unit constituting the fiber is tropocollagen having a molecular weight of about 300,000, a length of 280 nm, and a thickness of 1.5 nm.
  • composition which is an aspect of the present invention, may allow the filler to remain more naturally and longer in the skin after injecting the hyaluronic acid filler.
  • the present invention relates to a composition for promoting hyaluronic acid synthesis comprising a collagen hydrolyzate as an active ingredient.
  • the collagen hydrolyzate of the present invention may promote the synthesis of hyaluronic acid by its administration and may enhance the activity or amount of the up-stream enzymes or proteins involved in the synthesis of hyaluronic acid.
  • the present invention relates to a parenteral composition for inhibiting hyaluronidase activity comprising collagen hydrolyzate as an active ingredient.
  • the collagen hydrolyzate can inhibit or reduce the amount of hyaluronidase activity to prevent the degradation of hyaluronic acid and thus promote the synthesis of hyaluronic acid, and can maintain the efficacy of the filler for a long time.
  • the collagen hydrolyzate may include a collagen peptide, specifically, a collagen tripeptide.
  • the collagen peptide is a peptide having a molecular weight of 500 ⁇ 1,000 Da, it can be applied without limitation if the amino acid is bound by a peptide bond.
  • the collagen hydrolyzate refers to a substance obtained by hydrolyzing collagen and including a peptide having an average molecular weight of 500-5000 Da.
  • the collagen hydrolyzate may include more than 10% by weight of collagen tripeptide, based on the total weight of the collagen hydrolyzate, without being limited thereto, 7% or more, 9% or more, It may be more than 11%, more than 13%, more than 15%, more than 17%, more than 19%.
  • hyaluronic acid filler may refer to a filler based on hyaluronic acid (HA).
  • HA hyaluronic acid
  • the hyaluronic acid is one of complex polysaccharides composed of amino acids and uronic acids, and is a high molecular compound composed of N-acetylglucosamine and glucuronic acid.
  • the filler may refer to a complementary material which is directly injected or inserted into skin cells to fill wrinkles or dent scars.
  • the filler may be used for various purposes, such as to relieve curvature of the skin, replenishment of moisture, and the like, without limitation.
  • the filler may be performed over the entire body, and specifically, may include a face, a neck, and the like.
  • Maintaining the 'efficacy of the filler' herein includes increasing the content of hyaluronic acid, which is the main component of the filler, so that the injected filler degrades more slowly or promotes the synthesis of hyaluronic acid in vivo.
  • composition of the present invention can be used for a long time without limiting the effects such as relaxation of the skin curvature by the filler, filling of the feeling of moisture and the like.
  • the filler can slow the injection cycle, thereby reducing skin irritation and having an advantage of being economical.
  • parenteral refers to all kinds of administration methods other than oral administration, and may specifically mean transdermal, topical or subcutaneous administration, but is not limited thereto.
  • the composition may include 0.01 to 50% by weight of collagen hydrolyzate based on the total weight of the composition. Within this range, the composition may promote the synthesis of hyaluronic acid to maintain the efficacy of the hyaluronic acid filler for a long time. From the above point of view, the composition of the present invention is 0.05 to 48% by weight, 0.1 to 46% by weight, 0.5 to 44% by weight of the total composition, and the total weight of the composition. It may comprise 1 to 42% by weight relative to the total weight of the composition or 5 to 40% by weight of the collagen hydrolyzate.
  • the collagen peptide may include collagen tripeptides of Glycine (Gly) -X-Y, and X and Y may include all kinds of amino acids that are normally present in nature.
  • the X and Y may be the same or different kinds of amino acids.
  • the collagen hydrolyzate may comprise a collagen tripeptide of Gly-X-Y.
  • the amino acids are glycine (Glycine, Gly), alanine (Alanine, Ala), valine (Valine, Val) , Leucine, Leu, Isoleucine, Ile, Threonine, Thr, Serine, Serine, Cysteine, Cys, Methionine, Met, Aspartic acid, Asp Asparagine, Asn, Glutamic acid, Glu, Glutamine, Gln, Lysine, Lys, Arginine, Arg, Histidine, His, Phenylalanine, Phe ), Tyrosine (Tyr), tryptophan (Trp) and proline (Proline, Pro).
  • the collagen tripeptide may include glycine-proline-hydroxyproline, the X may be proline, and the Y may be hydroxyproline, but is not limited thereto.
  • the composition may be a pharmaceutical composition.
  • the composition when the composition according to the present invention is applied to medicines, the composition can be formulated into a parenteral dosage form in the form of a solid, semi-solid or liquid by adding a commercially available inorganic or organic carrier as the active ingredient.
  • preparations for parenteral administration include injections, drops, ointments, lotions, sprays, suspensions, emulsions, suppositories, and the like.
  • active ingredient of the present invention it can be easily formulated according to the conventional method, and surfactants, excipients, coloring agents, spices, preservatives, stabilizers, buffers, suspensions, and other commonly used auxiliaries can be suitably used.
  • composition according to the present invention may be administered parenterally, topically, transdermally, subcutaneously.
  • the dosage of the active ingredient will vary depending on the age, sex and weight of the subject to be treated, the specific disease or pathology to be treated, the severity of the disease or pathology, the route of administration and the judgment of the prescriber. Dosage determination based on these factors is within the level of skill in the art. Typical dosages are from 0.001 mg / kg / day to 2000 mg / kg / day, more specifically from 0.5 mg / kg / day to 1500 mg / kg / day.
  • the pharmaceutical composition of the present invention may be for removing or alleviating scars, and may be for reconstructing or restoring damaged or collapsed skin tissue.
  • the scar and damaged / collapsed skin tissue may mean that the trace remains on the skin due to various causes, for example, the surface of the skin may be uneven and recessed.
  • the cause may include, for example, an image or a wound.
  • the composition may be a cosmetic composition.
  • Cosmetic compositions according to the invention may be provided in all formulations suitable for topical application.
  • Emulsions, emulsions obtained by dispersing the aqueous phase in the oil phase in the form of solids, powders, foams, or softeners, astringents, nutrients, eye creams, nourishing creams, massage creams, cleansing creams, cleansing foams, cleansing water, It may be provided in the form of a powder, an essence, a pack.
  • Compositions of such formulations may be prepared according to conventional methods in the art.
  • the cosmetic composition according to the present invention may include other ingredients in addition to the above-mentioned substances within the range not impairing the main effect, preferably giving a synergistic effect to the main effect.
  • the cosmetic composition according to the present invention may further include a moisturizer, an emulsifier, a UV absorber, a preservative, a fungicide, an antioxidant, a pH adjuster, organic and inorganic pigments, flavors, coolants or limiting agents.
  • the blending amount of the above components can be easily selected by those skilled in the art within the range that does not impair the object and effect of the present invention, the blending amount may be 0.01 to 5% by weight, specifically 0.01 to 3% by weight based on the total weight of the composition. have.
  • the present invention in another aspect hyaluronic acid filler composition; It may be a filler surgical kit comprising a composition comprising a collagen hydrolyzate as an active ingredient.
  • the hyaluronic acid filler composition may be an injection.
  • the kit further includes instructions, and the instructions may be administered by injection injection of the hyaluronic acid, it may be disclosed that transdermal administration of the composition of another aspect of the present invention.
  • the filler may be applied to the skin surface to be absorbed into the skin and inserted into the skin.
  • the administration of the hyaluronic acid filler composition (hereinafter referred to as a filler procedure) may be by injection administration of a composition containing a hyaluronic acid filler, and is not limited to the number of times.
  • composition comprising the collagen hydrolyzate of the present invention may be used before the filler procedure.
  • the instructions may include transdermal administration of the collagen hydrolyzate-containing composition for 1 to 50 days, followed by injection administration of the hyaluronic acid filler composition.
  • the composition containing collagen hydrolyzate may be applied to the skin for 1 to 50 days, 10 to 50 days, 10 to 40 days, 10 to 30 days, 10 to 20 days, 20 to 50 days, 20 to 40 days, 20 days to After transdermal administration for 30 days, 25 days to 45 days, 25 days to 35 days, 30 days to 50 days, or 30 to 40 days, a filler procedure may be performed.
  • composition containing the collagen hydrolyzate may be used at the same time or after the filler treatment, or before or after the filler treatment.
  • transdermal administration may be performed after 1 to 20 days, 1 to 15 days, 1 to 10 days, 1 to 5 days, 1 to 4 days, 1 to 3 days, or 1 to 2 days.
  • the collagen hydrolyzate may be transdermally administered within 24 hours, 20 hours, 15 hours, 10 hours, 5 hours, 3 hours or 1 hour after the filler procedure.
  • the collagen hydrolyzate can prolong the efficacy duration of the filler by such use.
  • the collagen peptide used as an active ingredient in the present invention is purchased from Jellice Co., Ltd. (HATC, Jellice Co., JAPAN), a complex containing 15% or more of a tripeptide such as glycine-proline-hydroxyflorin form to be.
  • HaCaT cells a human-derived keratinocyte cell line (Dr NE Fusenig, Liebes Krebs utz Kunststoff utz, Heidelberg, Germany), were cultured in DMEM medium containing 10% FBS under conditions of 37 ° C. and 5% CO 2 .
  • Cells were cultured in 96 well plates, and when incubated at 80% or more, the cells were incubated for 24 hours in exchange for medium containing no FBS. Thereafter, the collagen peptide of Preparation Example 1 was dissolved in PBS at a concentration of 200 times and treated to a final concentration of 100 ppm and 200 ppm, respectively, and incubated for 24 hours. After 24 hours, the medium was recovered and used for a hyaluronic acid assay (HR assay), and cell viability quantitative assay (CCK8 assay) was performed using the remaining cells.
  • HR assay hyaluronic acid assay
  • CCK8 assay cell viability quantitative assay
  • collagen peptide was added 20 ⁇ L each to a final concentration of 0.2, 0.4, 0.6, 0.8, 1.0 mg / mL, and 12.5 mM 200 ⁇ L of CaCl 2 was mixed and incubated for 20 minutes on an aqueous solution at 37 ° C.
  • the control group was added with distilled water instead of collagen peptide and incubated for 20 minutes in an aqueous solution.
  • the collagen peptide was found to be excellent in inhibiting the activity of hyaluronidase.
  • the efficacy was confirmed to be dependent on the concentration of the collagen peptide.
  • nasolabial folds Six women who were required to improve their nasolabial folds were selected and divided into three groups, control and experimental groups.
  • the control group did not apply cosmetics containing collagen for one month
  • the experimental group applied cosmetics containing collagen to the face for one month.
  • the experimental group was injected with one filler into both nasolabial folds, and visited 15 days, 1 month, 2 months and 3 months after the injection for clinical evaluation.
  • Clinical evaluation was performed using the Wrinkle Severity Rating Scale (WSRS), which was evaluated by a specialist and evaluated on a 1 to 5 point scale. In Table 2, a lower score means no visible wrinkles.
  • WSRS Wrinkle Severity Rating Scale
  • GAIS global aesthetic improvement scale
  • the amount of the above ingredient was prepared per ampoule (2 ml).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Birds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention concerne une composition parentérale pour maintenir l'efficacité d'une charge pendant un long laps de temps, contenant un hydrolysat de collagène en tant que principe actif. La composition, conformément à la présente invention, permet de maintenir l'efficacité d'une charge d'acide hyaluronique pour un laps de temps prolongé, permettant ainsi le maintien de l'effet correspondant, indépendamment d'une fréquence réduite d'opérations de charge, et il existe donc également un avantage de réduction de l'irritation de la peau. De plus, il existe un avantage consistant à permettre un effet immédiat, étant donné qu'un procédé d'administration, en tant qu'administration parentérale, est simple et permet la pénétration directe dans la peau.
PCT/KR2015/002294 2014-03-20 2015-03-10 Composition pour maintenir l'efficacité d'une charge Ceased WO2015141978A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US15/127,399 US10279076B2 (en) 2014-03-20 2015-03-10 Composition for maintaining efficacy of filler
CN201580018372.XA CN106170309A (zh) 2014-03-20 2015-03-10 用于维持填充剂功效的组合物
SG11201607473PA SG11201607473PA (en) 2014-03-20 2015-03-10 Composition for maintaining efficacy of filler

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20140032945 2014-03-20
KR10-2014-0032945 2014-03-20
KR10-2015-0030409 2015-03-04
KR1020150030409A KR20150110332A (ko) 2014-03-20 2015-03-04 필러의 효능 유지용 조성물

Publications (1)

Publication Number Publication Date
WO2015141978A1 true WO2015141978A1 (fr) 2015-09-24

Family

ID=54144888

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2015/002294 Ceased WO2015141978A1 (fr) 2014-03-20 2015-03-10 Composition pour maintenir l'efficacité d'une charge

Country Status (1)

Country Link
WO (1) WO2015141978A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080109774A (ko) * 2006-03-13 2008-12-17 키쎄라 바이오파마슈티컬즈 인코포레이티드 유체 조직 증대 조성물 및 방법
KR20100025500A (ko) * 2008-08-27 2010-03-09 (주)아모레퍼시픽 콜라겐 펩티드를 함유하는 피부미용 개선용 조성물
KR20100101715A (ko) * 2009-03-10 2010-09-20 김민 피부 충전제 조성물
KR101082895B1 (ko) * 2008-12-12 2011-11-11 한남대학교 산학협력단 주사 주입이 용이한 미세입자 필러 시스템
KR101238730B1 (ko) * 2004-07-28 2013-03-04 카아길, 인코포레이팃드 콜라겐에 기초한 생리적 활성 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101238730B1 (ko) * 2004-07-28 2013-03-04 카아길, 인코포레이팃드 콜라겐에 기초한 생리적 활성 조성물
KR20080109774A (ko) * 2006-03-13 2008-12-17 키쎄라 바이오파마슈티컬즈 인코포레이티드 유체 조직 증대 조성물 및 방법
KR20100025500A (ko) * 2008-08-27 2010-03-09 (주)아모레퍼시픽 콜라겐 펩티드를 함유하는 피부미용 개선용 조성물
KR101082895B1 (ko) * 2008-12-12 2011-11-11 한남대학교 산학협력단 주사 주입이 용이한 미세입자 필러 시스템
KR20100101715A (ko) * 2009-03-10 2010-09-20 김민 피부 충전제 조성물

Similar Documents

Publication Publication Date Title
US11331305B2 (en) Peptides for skin rejuvenation and methods of using the same
JP5570978B2 (ja) 新規化合物、化粧品用途および薬用化粧品用途におけるその使用、および該化合物を含む組成物
US10279076B2 (en) Composition for maintaining efficacy of filler
WO2020045921A1 (fr) Composition pour améliorer la transparence de la peau et diminuer son aspect terne
WO2020006496A1 (fr) Compositions bioactives et procédés de traitement de la peau
US20100261658A1 (en) Peptide for activating aquaporin synthesis
AU2009256524B2 (en) Compositions for treating rosacea comprising chitosan and a dicarboxylic acid
US20100113385A1 (en) Complex combining an organic silicon derivative with hyaluronic acid calibrated fragments, for preventive and repairing action of cutaneous damages
CN111961119B (zh) 多肽在制备促进胶原蛋白分泌的药物或化妆品中的用途
JP2011042613A (ja) 抗老化用皮膚外用剤及び抗老化用化粧料
WO2015001891A1 (fr) Composition pour augmenter la production de collagène, pour augmenter la production d'élastine et/ou pour activer la migration des kératinocytes et son utilisation
WO2015141978A1 (fr) Composition pour maintenir l'efficacité d'une charge
AU2016302644A1 (en) CNP cyclic peptide, and medicine, external preparation and cosmetic each containing said cyclic peptide
CN118286107A (zh) 一种含有重组人源化ⅲ型胶原蛋白的多效组合物及其应用
JP2021035933A (ja) 外用組成物
US20220175712A1 (en) Use of caprylic and capric triglycerides for the treatment of a disease or condition mediated by filaggrin or collagen deficiency
TWI792375B (zh) 乳鐵蛋白的衍生胜肽及其促進及/或增加油脂生成的用途
KR20170067269A (ko) 이소바바찰콘을 포함하는 피부 개선용 조성물
JPH03123716A (ja) メラノサイト刺激ホルモン拮抗剤および該拮抗剤を含有する皮膚外用剤
WO2020111743A1 (fr) Peptide, composition et procédé de stimulation d'adipogenèse
JPH03123717A (ja) メラノサイト刺激ホルモン抑制剤および該抑制剤を含有する皮膚外用剤
WO2016159684A1 (fr) Composition pour favoriser la régénération cutanée contenant du sulfonate 2-mercaptoéthane de sodium
KR20150118394A (ko) 사이토카인 조합을 함유하는 피부 상태 개선용 조성물
HK1146730A (en) Novel compounds, use thereof in cosmetic and cosmeceutic applications, and compositions comprising same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15764390

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 15127399

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 25.11.2016)

122 Ep: pct application non-entry in european phase

Ref document number: 15764390

Country of ref document: EP

Kind code of ref document: A1